Literature DB >> 19662435

Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results.

Ruslan Dorfman1, Weili Li, Lei Sun, Fan Lin, Yongqian Wang, Andrew Sandford, Peter D Paré, Karen McKay, Hana Kayserova, Tereza Piskackova, Milan Macek, Kamila Czerska, Dorota Sands, Harm Tiddens, Sonia Margarit, Gabriela Repetto, Marci K Sontag, Frank J Accurso, Scott Blackman, Garry R Cutting, Lap-Chee Tsui, Mary Corey, Peter Durie, Julian Zielenski, Lisa J Strug.   

Abstract

Cystic fibrosis (CF) is a monogenic disease due to mutations in the CFTR gene. Yet, variability in CF disease presentation is presumed to be affected by modifier genes, such as those recently demonstrated for the pulmonary aspect. Here, we conduct a modifier gene study for meconium ileus (MI), an intestinal obstruction that occurs in 16-20% of CF newborns, providing linkage and association results from large family and case-control samples. Linkage analysis of modifier traits is different than linkage analysis of primary traits on which a sample was ascertained. Here, we articulate a source of confounding unique to modifier gene studies and provide an example of how one might overcome the confounding in the context of linkage studies. Our linkage analysis provided evidence of a MI locus on chromosome 12p13.3, which was segregating in up to 80% of MI families with at least one affected offspring (HLOD = 2.9). Fine mapping of the 12p13.3 region in a large case-control sample of pancreatic insufficient Canadian CF patients with and without MI pointed to the involvement of ADIPOR2 in MI (p = 0.002). This marker was substantially out of Hardy-Weinberg equilibrium in the cases only, and provided evidence of a cohort effect. The association with rs9300298 in the ADIPOR2 gene at the 12p13.3 locus was replicated in an independent sample of CF families. A protective locus, using the phenotype of no-MI, mapped to 4q13.3 (HLOD = 3.19), with substantial heterogeneity. A candidate gene in the region, SLC4A4, provided preliminary evidence of association (p = 0.002), warranting further follow-up studies. Our linkage approach was used to direct our fine-mapping studies, which uncovered two potential modifier genes worthy of follow-up.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19662435      PMCID: PMC2888886          DOI: 10.1007/s00439-009-0724-8

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  53 in total

1.  Quantification of type I error probabilities for heterogeneity LOD scores.

Authors:  Paula C Abreu; Susan E Hodge; David A Greenberg
Journal:  Genet Epidemiol       Date:  2002-02       Impact factor: 2.135

2.  Effect of misspecification of gene frequency on the two-point LOD score.

Authors:  D K Pal; M Durner; D A Greenberg
Journal:  Eur J Hum Genet       Date:  2001-11       Impact factor: 4.246

3.  A comparison of bayesian methods for haplotype reconstruction from population genotype data.

Authors:  Matthew Stephens; Peter Donnelly
Journal:  Am J Hum Genet       Date:  2003-10-20       Impact factor: 11.025

4.  Loci of intestinal distress in cystic fibrosis knockout mice.

Authors:  Christina K Haston; Lap-Chee Tsui
Journal:  Physiol Genomics       Date:  2003-01-15       Impact factor: 3.107

5.  Analysis of DNA polymorphism haplotypes linked to the cystic fibrosis locus in North American black and Caucasian families supports the existence of multiple mutations of the cystic fibrosis gene.

Authors:  G R Cutting; S E Antonarakis; K H Buetow; L M Kasch; B J Rosenstein; H H Kazazian
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

6.  Effects of misspecifying genetic parameters in lod score analysis.

Authors:  F Clerget-Darpoux; C Bonaïti-Pellié; J Hochez
Journal:  Biometrics       Date:  1986-06       Impact factor: 2.571

7.  A comparison of sib-pair linkage tests for disease susceptibility loci.

Authors:  W C Blackwelder; R C Elston
Journal:  Genet Epidemiol       Date:  1985       Impact factor: 2.135

8.  Impaired pancreatic ductal bicarbonate secretion in cystic fibrosis.

Authors:  M Soleimani
Journal:  JOP       Date:  2001-07

Review 9.  Coordination of pancreatic HCO3- secretion by protein-protein interaction between membrane transporters.

Authors:  M G Lee; W Ahn; J A Lee; J Y Kim; J Y Choi; O W Moe; S L Milgram; S Muallem; K H Kim
Journal:  JOP       Date:  2001-07

10.  Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas.

Authors:  N Ahmed; M Corey; G Forstner; J Zielenski; L-C Tsui; L Ellis; E Tullis; P Durie
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

View more
  23 in total

1.  Initial interrogation, confirmation and fine mapping of modifying genes: STAT3, IL1B and IFNGR1 determine cystic fibrosis disease manifestation.

Authors:  Heike Labenski; Silke Hedtfeld; Tim Becker; Burkhard Tümmler; Frauke Stanke
Journal:  Eur J Hum Genet       Date:  2011-07-06       Impact factor: 4.246

2.  The influence of genetics on cystic fibrosis phenotypes.

Authors:  Michael R Knowles; Mitchell Drumm
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

3.  Cystic fibrosis newborn screening: distribution of blood immunoreactive trypsinogen concentrations in hypertrypsinemic neonates.

Authors:  Valentina Paracchini; Manuela Seia; Sara Raimondi; Lucy Costantino; Patrizia Capasso; Luigi Porcaro; Carla Colombo; Domenico A Coviello; Tiziana Mariani; Emanuela Manzoni; Monica Sangiovanni; Carlo Corbetta
Journal:  JIMD Rep       Date:  2011-11-04

Review 4.  The divergence, actions, roles, and relatives of sodium-coupled bicarbonate transporters.

Authors:  Mark D Parker; Walter F Boron
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

5.  Parent-of-origin effects of FAS and PDLIM1 in attention-deficit/hyperactivity disorder.

Authors:  Ke-Sheng Wang; Xuefeng Liu; Qunyuan Zhang; Nagesh Aragam; Yue Pan
Journal:  J Psychiatry Neurosci       Date:  2012-01       Impact factor: 6.186

6.  Meconium ileus in cystic fibrosis is not linked to central repetitive region length variation in MUC1, MUC2, and MUC5AC.

Authors:  XueLiang Guo; Rhonda G Pace; Jaclyn R Stonebraker; Wanda K O'Neal; Michael R Knowles
Journal:  J Cyst Fibros       Date:  2014-06-08       Impact factor: 5.482

Review 7.  Modifier genes in Mendelian disorders: the example of cystic fibrosis.

Authors:  Garry R Cutting
Journal:  Ann N Y Acad Sci       Date:  2010-12       Impact factor: 5.691

8.  Noninvasive analysis of the sputum transcriptome discriminates clinical phenotypes of asthma.

Authors:  Xiting Yan; Jen-Hwa Chu; Jose Gomez; Maria Koenigs; Carole Holm; Xiaoxuan He; Mario F Perez; Hongyu Zhao; Shrikant Mane; Fernando D Martinez; Carole Ober; Dan L Nicolae; Kathleen C Barnes; Stephanie J London; Frank Gilliland; Scott T Weiss; Benjamin A Raby; Lauren Cohn; Geoffrey L Chupp
Journal:  Am J Respir Crit Care Med       Date:  2015-05-15       Impact factor: 21.405

9.  All-cause mortality benefit of coronary revascularization vs. medical therapy in patients without known coronary artery disease undergoing coronary computed tomographic angiography: results from CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter Registry).

Authors:  James K Min; Daniel S Berman; Allison Dunning; Stephan Achenbach; Mouaz Al-Mallah; Matthew J Budoff; Filippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Victor Cheng; Kavitha Chinnaiyan; Benjamin J W Chow; Ricardo Cury; Augustin Delago; Gudrun Feuchtner; Martin Hadamitzky; Joerg Hausleiter; Philipp Kaufmann; Ronald P Karlsberg; Yong-Jin Kim; Jonathon Leipsic; Fay Y Lin; Erica Maffei; Fabian Plank; Gilbert Raff; Todd Villines; Troy M Labounty; Leslee J Shaw
Journal:  Eur Heart J       Date:  2012-10-09       Impact factor: 29.983

Review 10.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.